Significant biosimilar activities this week include 31 Jul 20 | US | Vizient has advised its member health groups to utilise biosimilars to hedge against drug price inflation and...
Pearce IP BioBlast™: w/e 07 August 2020
read more
Pearce IP BioBlast™: w/e 31 July 2020
Significant biosimilar activities this week include 27 Jul 20 | EU | Celltrion announced the European Commission has granted marketing authorisation for Remsima®...
Pearce IP BioBlast™: w/e 24 July 2020
Significant biosimilar activities this week include 20 Jul 20 | EU | Spherix reported that the EU market for AbbVie's Humira® has been negatively impacted by gastroenterologists...
Pearce IP BioBlast™: w/e 17 July 2020
Significant biosimilar activities this week include 09 Jul 20 | AU | The Australian Generic and Biosimilar Medicines Association (GBMA) announced it reached over 540,000...
Pearce IP BioBlast™: w/e 10 July 2020
Significant biosimilar activities this week include 05 Jul 20 | In its 2019-2020 Annual Report, Biocon announced it plans to list Biocon Biologics on Indian markets within the...
USPTO Creates Program to Resolve Ex Parte Appeals in 6 Months
The United States Patent and Trademark Office (USPTO) announced a pilot program to fast track appeals to the Patent Trial and Appeal Board (PTAB) from adverse decisions of...
Pearce IP BioBlast™: w/e 03 July 2020
Significant biosimilar activities this week include 28 Jun 20 | US Genentech filed a complaint against Samsung Bioepis in the District Court of Delaware under the BPCIA, alleging...
The Australian Federal Court teaches generic how to avoid infringement of Swiss-style claims
The enlarged bench of the Full Court of the Australian Federal Court has clarified what constitutes infringement of Swiss-style claims in Mylan Health Pty Ltd v Sun Pharma ANZ...
New Thinking for New Science- Biopharmaceutical Patent Disputes in Australia
First published as: Pearce et al, 'New Thinking for New Science - Biopharmaceutical Patent Disputes in Australia' (2020) 120 Intellectual Property Forum 33. As we consider the...
Pearce IP BioBlast™: w/e 26 Jun 2020
Significant biosimilar activities this week include June 20 | The NZ Herald reported a new study by NZ scientists which indicates that transgenic goats are capable of producing...
Is your patent attorney building a straw shack when you need a brick fortress?
We all know the story. Three little pigs leave home to seek their fortunes, and make houses out of either straw, sticks or bricks. Every child knows that the brother pigs who...
IAM Patent 1000: Pearce IP patent leaders ranked among world’s best
Boutique specialist patent firm Pearce IP is proud to report a strong presence in the prestigious IAM Patent 1000 ranking of the world's top patent professionals for 2020....
Pearce IP BioBlast™: w/e 12 Jun 2020
Significant biosimilar activities this week include 08 Jun 20 | The Centre for Biosimilars reported that the WHO certified Celltrion's Truxima® (rituximab) in its...
Pearce IP BioBlast™: w/e 05 Jun 2020
Significant biosimilar activities this week include 29 May 20 | In a filing to the Securities and Exchange Commission, Alexion announced it has settled its eculizumab dispute...
Pearce IP BioBlast™: w/e 29 May 2020
Significant biosimilar activities this week include 25 May 20 | The American Journal of Managed Care reported two cost savings studies presented at a virtual meeting of the...
Pearce IP appoints biotech/pharma IP leader Jacinta Flattery-O’Brien as Special Counsel
Boutique specialist firm Pearce IP is delighted to announce the appointment of biotech/pharma IP leader Jacinta Flattery-O'Brien PhD as Special Counsel. A highly regarded patent...
Pearce IP BioBlast™: w/e 22 May 2020
Significant biosimilar activities this week include 11 May 20 | AstraZeneca announced it had recovered the global rights to brazikumab from Amgen. AstraZeneca had previously...
Pearce IP BioBlast™: w/e 15 May 2020
Significant biosimilar activities this week include 11 May 20 | Healio reported on a new study comparing faricimab to ranibizumab which was presented at a virtual meeting of the...
Pearce IP BioBlast™: w/e 08 May 2020
Significant biosimilar activities this week include 01 May 2020 | AbbVie released its Q1 2020 financial results, reporting a 13.7% increase in US sales of Humira® (adalimumab)...
Pearce IP BioBlast™: w/e 01 May 2020
Significant biosimilar activities this week include 23 April 2020 | Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02....
Pearce IP BioBlast™: w/e 24 Apr 2020
Significant biosimilar activities this week include 21 Apr 20 | The Centre for Biosimilars reported that Xbrane Pharma was continuing clinical trials of its ranibizumab candidate...
Pearce IP BioBlast™: w/e 17 Apr 2020
Significant biosimilar activities this week include 14 April 20 | Mylan and Biocon launched Fulphila® (pegfilgrastim) in Australia. Fulphila® is indicated for the treatment of...
Pearce IP BioBlast™: w/e 10 Apr 2020
Significant biosimilar activities this week include March 20 | BiosanaPharma released the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®. 06...
Pearce IP BioBlast™: w/e 03 Apr 2020
Significant biosimilar activities this week include 30 Mar 20 | Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab)...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.